Treatment of Relapsed Enterococcal Prostatitis

Primary Treatment Regimen

• The American College of Cardiology is not relevant here, however, for enterococcal prostatitis that has relapsed after 4 weeks of daptomycin, switch to high-dose daptomycin (10-12 mg/kg/day) combined with ampicillin (if susceptible) for 8 weeks, with mandatory weekly CPK monitoring 1
• High-dose daptomycin 10-12 mg/kg/day IV for 8 weeks produces sustained bactericidal activity 1
• Add ampicillin 2g IV every 6 hours (total 8g/day) if the isolate is ampicillin-susceptible, as daptomycin plus beta-lactam combinations provide synergistic bactericidal activity 1

Alternative Regimen for Beta-Lactam Resistant or Intolerant Cases

• Linezolid 600 mg PO or IV every 12 hours for 6 weeks is effective for chronic enterococcal prostatitis with success rates of 80-86% 2

Critical Monitoring Requirements

• Weekly CPK levels are mandatory during extended high-dose daptomycin therapy due to the risk of myopathy 1
• Complete blood count weekly if using linezolid (>2 weeks) due to myelosuppression risk 2

Antibiotic Susceptibility Testing

• Obtain comprehensive susceptibility testing, including ampicillin/penicillin susceptibility (MIC determination), vancomycin susceptibility, high-level gentamicin resistance, and susceptibility to daptomycin and linezolid if resistant to other antibiotics 3

Expected Timeline for Response

• Initial symptom improvement typically occurs within 5-7 days, with more complete clinical response in 10-14 days 2
• Microbiological documentation of cure at 2-4 weeks 1

Infectious Disease Consultation

• Management of relapsed enterococcal infections should involve infectious disease consultation as standard of care 4, 5

Treatment of Relapsed Enterococcal Prostatitis

Introduction to Relapsed Enterococcal Prostatitis Treatment

• The American Heart Association recommends combination therapy with daptomycin and ampicillin or ceftaroline, especially in patients with persistent bacteremia or enterococcal strains with high MICs to daptomycin 6, 7
• There are insufficient data to recommend monotherapy with daptomycin for the treatment of multidrug-resistant enterococcal infections, even in endocarditis which has more published data than prostatitis 6, 7
• The American Heart Association explicitly states that daptomycin failures have been documented in enterococcal infections, with some failures resulting from emergence of daptomycin-resistance during treatment 7

Combining Amoxicillin with Daptomycin for Enterococcal Prostatitis

Rationale for Combination Therapy

• The American Heart Association guidelines state that ampicillin and ceftaroline in combination with daptomycin demonstrate the greatest synergistic activity compared with other β-lactam–daptomycin combinations for enterococcal infections 8
• The combination of amoxicillin and daptomycin is strongly recommended for enterococcal prostatitis, particularly when dealing with resistant strains or persistent infection, as beta-lactam-daptomycin combinations demonstrate superior synergistic bactericidal activity compared to daptomycin monotherapy 8

Specific Dosing Recommendations

• Daptomycin 10-12 mg/kg/day IV, plus amoxicillin 200 mg/kg/day IV in 4-6 divided doses, is recommended for beta-lactam susceptible strains 8, 9

Indications for Combination Therapy

• Combination therapy with daptomycin and ampicillin should be considered especially in patients with persistent bacteremia 9
• Combination therapy with daptomycin and ampicillin should be considered especially in patients with enterococcal strains with high MICs (≥3 μg/mL) to daptomycin within the susceptible range 8, 9

Guideline Recommendations

• The American Heart Association explicitly recommends the combination of daptomycin and ampicillin as Class IIb, Level of Evidence C for resistant enterococcal infections 9

Daptomycin Monotherapy for Enterococcus faecalis Prostatitis

Introduction to Treatment Guidelines

• The American Heart Association explicitly states there are insufficient data to recommend daptomycin monotherapy for multidrug-resistant enterococcal infections, with documented treatment failures including emergence of daptomycin-resistance during therapy 10
• Daptomycin monotherapy shows inferior outcomes compared to combination therapy in bloodstream infections, which have more published data than prostatitis 11

Recommended Treatment Approach

• The American College of Cardiology recommends using linezolid 600 mg every 12 hours as first-line therapy, or if daptomycin must be used, employ high-dose daptomycin (10-12 mg/kg/day) combined with ampicillin rather than monotherapy 10
• High-dose daptomycin with beta-lactam combination had adjusted hazard ratios of 19.01 (p=0.002) for survival compared to monotherapy 11
• Daptomycin 10-12 mg/kg/day combined with ceftaroline demonstrates synergistic activity in vitro 12, 10

Critical Considerations for Treatment

• Higher daptomycin MICs (3-4 mg/mL) are associated with treatment failure (OR=3.23, p=0.013) even with combination therapy 11
• Combination therapy becomes especially critical when enterococcal strains have MICs ≥3 μg/mL within the susceptible range 10
• Management of relapsed enterococcal infections requires ID consultation as standard of care 10
• Patients with poor treatment response or those requiring prolonged therapy need specialist input 12